Minor insider divestment
PHI Board member Jan Richardsson recently divested 5 328 shares in the company.
“The reason for the sale is that I needed to balance an option loss linked to a previous employment”, comments Richardsson.
After the sale, Richardsson owns 38 634 shares in PHI, privately and via companies.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.